NCT07469540 Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis
| NCT ID | NCT07469540 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Jérôme Bouchan |
| Condition | Aerobic Exercise |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-03-16 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2026-03-16 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to determine whether an aerobic exercise program can reduce cardiovascular risk in patients with systemic inflammation, such as those with rheumatoid arthritis and chronic kidney disease. The main questions this study aims to address are: * Does an individualized aerobic exercise program reduce cardiovascular risk, as assessed arterial stiffness and endothelial function ? * What are the effects of this exercise program on inflammation and immunosenescence? Researchers will compare an individualized aerobic exercise program with a therapeutic education program (consisting of educational phone calls only) and a control group with no intervention. Participants will: * Perform three physical activity sessions per week for six weeks (45-minute sessions at 60-80% of heart rate reserve); * Attend clinic visits at baseline, after the 6-week intervention, and at a 6-week follow-up after the intervention; * Undergo assessments including pulse wave velocity, hyperemic reactivity, and blood analyses.
Eligibility Criteria
Inclusion Criteria: * Diagnosis of Chronic Kidney Disease (CKD) or Rheumatoid Arthritis (RA), with no other risk factors related to the disease. * Having a glomerular filtration rate between 45 and 20 ml/min/1.73 m², corresponding to stages III and IV not on dialysis for patients with CKD ; or have a DAS 28 score ≥ 2.6 points for patients with RA. * Have a medical certificate stating that there are no adverse reactions to physical activity. * Affiliation with a French social security scheme or beneficiary of such a scheme. Exclusion Criteria: * Unstabilised corticosteroid therapy and/or \>10mg prednisone/day * Uncontrolled high blood pressure * Pregnant women * Impaired higher functions making it impossible to understand and adhere to an aerobic exercise program * Inability to perform physical exercise, regardless of the cause (neurological, central or peripheral, cardiovascular or respiratory, or musculoskeletal) * Legal incapacity or limited legal capacity * Subject unlikely to cooperate with the study and/or low cooperation anticipated by the investigator * Subject without health insurance * Subject is in the exclusion period of another study involving human subjects that may interfere with the results of this study, particularly by affecting inflammatory status and the cardiovascular system.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07469540 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, studying Aerobic Exercise. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07469540 currently recruiting?
Yes, NCT07469540 is actively recruiting participants. Contact the research team at jerome.bouchan@umlp.fr for enrollment information.
Where is the NCT07469540 trial being conducted?
This trial is being conducted at Besançon, France.
Who is sponsoring the NCT07469540 clinical trial?
NCT07469540 is sponsored by Jérôme Bouchan. The trial plans to enroll 90 participants.